Loading clinical trials...
Loading clinical trials...
MicroRNA-210 (miR-210) can be a potential therapeutic target of patients with peripheral artery disease (PAD). Recent evidence suggests the role of miR-210 and oxidative stress in the pathophysiology ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of West Florida
Collaborators
NCT06112171 · Peripheral Arterial Disease
NCT03663777 · Peripheral Arterial Disease
NCT07497360 · Peripheral Arterial Disease
NCT04584632 · Peripheral Arterial Disease, Vascular Diseases, and more
NCT07157475 · Peripheral Arterial Disease(PAD)
UT Austing Dell Medical School
Austin, Texas
Baylor Scott and White
Temple, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions